Brain. 2023 May 16:awad162. doi: 10.1093/brain/awad162. Online ahead of print.

ABSTRACT

Dopaminergic medication is well established to boost reward- versus punishment-based learning in Parkinson’s disease. However, there is tremendous variability in dopaminergic medication effects across different individuals, with some patients exhibiting much greater cognitive sensitivity to medication than others. We aimed to unravel the mechanisms underlying this individual variability in a large heterogeneous sample of early-stage patients with Parkinson’s disease as a function of comorbid neuropsychiatric symptomatology, in particular impulse control disorders and depression. One hundred and ninety-nine patients with Parkinson’s disease (138 ON medication and 61 OFF medication) and 59 healthy controls were scanned with functional magnetic resonance imaging while they performed an established probabilistic instrumental learning task. Reinforcement learning model-based analyses revealed medication group differences in learning from gains versus losses, but only in patients with impulse control disorders. Furthermore, expected-value related brain signaling in the ventromedial prefrontal cortex was increased in patients with impulse control disorders ON medication compared with those OFF medication, while striatal reward prediction error signaling remained unaltered. These data substantiate the hypothesis that dopamine’s effects on reinforcement learning in Parkinson’s disease vary with individual differences in comorbid impulse control disorder and suggest they reflect deficient computation of value in medial frontal cortex, rather than deficient reward prediction error signaling in striatum.

PMID:37192341 | DOI:10.1093/brain/awad162